2014 Fiscal Year Final Research Report
A study of tumor-specific T cell therapy for canine melanoma cell lines.
| Project/Area Number |
25850204
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Veterinary medical science
|
|---|
| Research Institution | Obihiro University of Agriculture and Veterinary Medicine |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2013-04-01 – 2015-03-31
|
| Keywords | 獣医学 / 臨床 / 癌 / 免疫学 / 悪性黒色腫 / 犬 |
|---|
| Outline of Final Research Achievements |
Canine malignant melanoma is one of the intractable diseases. In order to develop the new treatment, we focused the CD3-activated T cell (CAT) therapy. To improve it for increasing the specificity for melanoma, we used DH82, melanoma-associated peptides, and anti Gpnmb antibody. However, these combinations did not promote the proliferation of lymphocytes, and not enhance the anti tumor activity of CAT, either. On the other hand, canine melanoma cells (CMM2) was administered subcutaneously into nu/nu mice, and simultaneously injected with CAT or CAT pulsed by melanoma-associated peptides. Then, CAT or CAT pulsed by peptides inoculation caused significantly lower tumor growth than saline’s one. In conclusion, CAT certainly showed an anti-tumor activity in nu/nu mice, but further studies were necessary for more improvement of CAT therapy.
|
| Free Research Field |
腫瘍免疫学
|
